IQVIA: Increasingly Indispensable In Drug Development

IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record $32.4B backlog, technology-driven margin expansion, and robust buyback-enhanced EPS growth. IQV's unique, comprehensive data assets and AI-enabled services create a defensible moat, insulating it from both Big Tech and CRO competition.

Seeking Alpha • Dec 11, 2025

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 9, 2025

IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA's Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital transformation of healthcare and life sciences, aiming to revolutionize cli.

Business Wire • Dec 2, 2025

Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 27, 2025

Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors

Alibaba Group was a contributor during the quarter. The stock price rose significantly following earnings that reflected rapid Chinese AI growth. Alphabet was a contributor during the quarter. The stock price appreciated following a favorable ruling in the Google Search antitrust case and Q2 earnings that exceeded expectations across the board. Charter Communications was a detractor during the quarter. The broadband leader's stock price declined after it reported weak second-quarter earnings.

Seeking Alpha • Nov 12, 2025

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

IQVIA Holdings Inc. ( IQV ) UBS Global Healthcare Conference 2025 November 11, 2025 12:30 PM EST Company Participants Ari Bousbib - CEO & Chairman Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. We're live.

Seeking Alpha • Nov 11, 2025

Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation

Warner Bros Discovery reported merger with Paramount-Skydance could generate meaningful cost synergies and create a scaled competitor with a deep and unmatched content library. Innovations in the Google Search experience are driving both engagement and revenue benefits for Alphabet. IQVIA's R&D solutions business showed signs of gaining share, with its win rate improving significantly.

Seeking Alpha • Nov 7, 2025

IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 5, 2025

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Ho.

Business Wire • Nov 5, 2025

IQVIA narrows annual profit forecast amid continued research contract cancellations

IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the second half of this year.

Reuters • Oct 28, 2025